Since beginning to work remotely at the start of COVID-19, our team has found ways to build and maintain momentum in identifying new research projects, working on new grant applications and publishing prior work. Over the past few months, G2P faculty have attended numerous virtual conferences, been featured in the news and media, and contributed … Continued
This Fall, G2P launched the Brigham Preventive Genomics Clinic, the first ever to offer comprehensive sequencing to healthy adults and children. We also hosted the PopSeq Inaugural Retreat in Boston to kick-off the first ever study to return unanticipated genetic findings to African Americans and examine rare diseases in population-based cohorts. Check out the new … Continued
Genome sequencing (GS) is increasingly conducted in large-scale human research studies, creating questions for investigators about whether and how to return genetic findings. The American College of Medical Genetics and Genomics (ACMG) recommends that physicians report secondary findings in at least 59 actionable genes (the ACMG59) whenever clinical GS is ordered. In an effort to … Continued
Continuous new discoveries about the genome make updates important.
G2P’s summer began with our team members participating in the Boston Athletic Association 10K on Sunday June 23rd! Over the past few months, G2P faculty have attended numerous conferences nationwide, been featured in podcasts discussing the new preventive genomics clinic, and engaged with leaders in science, business, and industry in support of the Franca Fund.
The collaboration between Sanford Health and Harvard Medical will help guide best practices for offering genetic testing to patients and improving health outcomes
Spring saw accomplishments by team members through numerous projects. G2P officially kicked-off the PeopleSeq consortium in Boston this January! Our very own, Carrie Blout, MS, CGC, was one of 86 Partner’s individuals awarded the Partners In Excellence Award.
Carrie Blout, MS, CGC, Director of Research Development and Senior genetic Counselor at Genomes2People was selected as a 2019 Individual recipient of the Partners In Excellence Awards- awarded to individuals at Partners HealthCare for going above and beyond in their work efforts.
The PeopleSeq Consortium officially kicked off their NIH- funded project in Boston, bringing together a cohort of leading academic and industry collaborators.
Researchers analyzed nearly 5,000 genes looking for the risk of diseases and found that almost 10 percent of babies tested were at risk for a condition that could be treated early.
Press Brief: The BabySeq project reports that out of the 159 newborns that were randomized to receive genomic sequencing, 15 were found to have a genetic variant for which there was a strong evidence of increased risk of a disorder that presents or is clinically manageable during childhood.
This Fall, G2P has had exciting updates with a new PeopleSeq grant. Our team has traveled from San Diego, Atlanta, and Fort Detrick to Basel, Zurich, and Barcelona, to several conferences, presenting new data from our translational genomics research projects.
From San Diego, Atlanta and Fort Detrick to Basel, Zurich and Barcelona, our team traveled to several conferences this fall, presenting new data from our translational genomics research projects.
While a good deal of research has focused on finding information within the human genome that can diagnose rare conditions, far less work has been done to understand the longer-term consequences of identifying genetic risks in apparently healthy people. Read more the PeopleSeq Consoritum from the principal investigator, Dr. Robert Green!
Sequencing in the military healthcare setting comes with a unique set of considerations as it has the potential to return information that may impact a service member’s perceived mission-readiness, duty assignments, and career. Although scholars have commented on this issue, little is known about the perspectives of those serving in the military. The MilSeq Project … Continued
Everyone talks about generating the clinical utility data necessary to integrate genomics into healthcare, but no one has taken this to heart more, or generated more of it, than Dr. Robert Green.
Genome sequencing services are increasingly being utilized by physicians and their patients in both research and clinical settings. Developing standards and procedures for the use of sequencing information in clinical medicine is an urgent need with numerous obstacles to integrity and storage of sequencing data, interpretation, and responsible clinical integration. The MedSeq Project, funded by … Continued
Currently, the risks and benefits of genomic sequencing for newborns are not well understood. All newborns receive a state-mandated heel stick blood test shortly after birth in order to screen for approximately 30 heritable, treatable conditions such as blood, endocrine, and metabolic disorders. Genomic sequencing has the potential to allow for significantly more extensive screening of … Continued
The rapid identification of genetic risk factors for common, complex diseases poses great opportunities and challenges for public health. Genetic information is increasingly being utilized as part of commercial efforts, including personal genomic testing, to provide consumers with genetic risk information related to common diseases. Few empirical data have been gathered to understand the characteristics … Continued
Alzheimer’s disease (AD) clinical trials have traditionally tested individuals with symptoms of dementia, but the discovery of AD biomarkers has dramatically altered this approach. New studies are enrolling participants who are cognitively normal but have biomarkers suggestive of “preclinical AD” with the hopes of delaying the onset of cognitive impairment. Of critical importance is whether … Continued
Genomic sequencing is available to and being utilized by physicians and their patients in both research and clinical settings. Instead of using genomic technology in the hopes of identifying a cause for a specific condition, genomic sequencing in healthy individuals would follow a model of “predispositional” genomic testing. This model envisions results being returned in a … Continued
The Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) Study, funded by NIH, was the first ever study to disclose APOE Alzheimer’s Disease risk to healthy patients and made important contributions to the scientific understanding of disclosing genetic risk for Alzheimer’s Disease.Through a series of multi-site randomized controlled clinical trials, REVEAL provided empirical data to address ethical, … Continued